Penumbra Inc
NYSE:PEN
US |
Fubotv Inc
NYSE:FUBO
|
Media
|
|
US |
Bank of America Corp
NYSE:BAC
|
Banking
|
|
US |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
|
US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
US |
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
|
CN |
NIO Inc
NYSE:NIO
|
Automobiles
|
|
US |
Fluor Corp
NYSE:FLR
|
Construction
|
|
US |
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
|
US |
TopBuild Corp
NYSE:BLD
|
Consumer products
|
|
US |
Abbott Laboratories
NYSE:ABT
|
Health Care
|
|
US |
Chevron Corp
NYSE:CVX
|
Energy
|
|
US |
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
|
US |
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
|
US |
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
|
US |
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
|
US |
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
163.64
273.15
|
Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
Fubotv Inc
NYSE:FUBO
|
US | |
Bank of America Corp
NYSE:BAC
|
US | |
Palantir Technologies Inc
NYSE:PLTR
|
US | |
C
|
C3.ai Inc
NYSE:AI
|
US |
Uber Technologies Inc
NYSE:UBER
|
US | |
NIO Inc
NYSE:NIO
|
CN | |
Fluor Corp
NYSE:FLR
|
US | |
Jacobs Engineering Group Inc
NYSE:J
|
US | |
TopBuild Corp
NYSE:BLD
|
US | |
Abbott Laboratories
NYSE:ABT
|
US | |
Chevron Corp
NYSE:CVX
|
US | |
Occidental Petroleum Corp
NYSE:OXY
|
US | |
Matrix Service Co
NASDAQ:MTRX
|
US | |
Automatic Data Processing Inc
NASDAQ:ADP
|
US | |
Qualcomm Inc
NASDAQ:QCOM
|
US | |
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one PEN stock under the Base Case scenario is 106.95 USD. Compared to the current market price of 244.84 USD, Penumbra Inc is Overvalued by 56%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Penumbra Inc
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for PEN cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Penumbra Inc. is revolutionizing the landscape of medical technology with its innovative solutions tailored to treat some of the most challenging conditions in neuro and peripheral vascular health. Founded in 2004, the company has swiftly positioned itself as a leader in developing devices that empower physicians to provide advanced, minimally invasive treatment options. Penumbra's flagship products, including the Penumbra System for thrombectomy and its suite of neurovascular devices, showcase its commitment to enhancing patient outcomes and streamlining procedures. With a strong focus on research and development, the company aims to address unmet medical needs, thus facilitating its growth...
Penumbra Inc. is revolutionizing the landscape of medical technology with its innovative solutions tailored to treat some of the most challenging conditions in neuro and peripheral vascular health. Founded in 2004, the company has swiftly positioned itself as a leader in developing devices that empower physicians to provide advanced, minimally invasive treatment options. Penumbra's flagship products, including the Penumbra System for thrombectomy and its suite of neurovascular devices, showcase its commitment to enhancing patient outcomes and streamlining procedures. With a strong focus on research and development, the company aims to address unmet medical needs, thus facilitating its growth trajectory in a market with substantial demand.
As an investment opportunity, Penumbra Inc. stands out not only for its robust pipeline of innovative technologies but also for its impressive financial performance. The company has demonstrated strong revenue growth driven by increasing market adoption of its products and strategic expansions into new therapeutic areas. With healthcare's ongoing shift toward minimally invasive treatments, Penumbra is ideally positioned to capitalize on this trend, supported by a team of experienced professionals and a culture of innovation. For investors, Penumbra offers a compelling blend of growth prospects and the potential for long-term returns as it continues to redefine standards of care in the medical device industry.
Penumbra, Inc. is a medical device company that focuses on developing innovative products for the neuro and peripheral vascular markets. The company's core business segments primarily include:
-
Neurovascular: This segment deals with devices used in the treatment of conditions affecting the brain's blood vessels, such as ischemic stroke and cerebral aneurysms. The product offerings typically include mechanical thrombectomy devices for clot removal and other tools aimed at enhancing acute care.
-
Peripheral Vascular: This segment focuses on developing and providing solutions for diseases affecting the peripheral blood vessels, which can include conditions like peripheral artery disease (PAD). Products in this area may include thrombectomy devices, access products, and other interventional tools used in peripheral vascular interventions.
-
Other Products and Services: Penumbra also engages in broader medical technology services, including research and development activities, and may offer consulting and support services to healthcare providers.
Overall, Penumbra's core business segments leverage advanced technology and innovative solutions aimed at improving patient outcomes in neurovascular and peripheral vascular health. The company's strategy involves continuous investment in R&D to expand its product lines and enhance its competitive position in these markets.
Penumbra, Inc. possesses several unique competitive advantages that distinguish it in the medical device industry, particularly in the neuro and peripheral vascular markets. Here are some of the key advantages:
-
Innovative Technology and Product Development: Penumbra is known for its cutting-edge technologies, particularly in the treatment of neurovascular and peripheral vascular conditions. The company's focus on innovation allows it to develop products that address unmet medical needs, positioning it ahead of competitors.
-
Strong Intellectual Property Portfolio: Penumbra holds a substantial number of patents covering its technologies and processes. This robust intellectual property protects its innovations from competitors, helping to maintain a competitive edge.
-
Focused Specialty: By concentrating on specific medical fields such as neurovascular interventions and thrombectomy systems, Penumbra can better allocate resources to research and development, resulting in specialized products that cater to niche markets.
-
Clinical Evidence and Regulatory Success: The company has established a track record of obtaining regulatory approvals (like FDA clearances) for its groundbreaking devices. Strong clinical data supporting the efficacy and safety of its products aids in gaining physician confidence and market acceptance.
-
Strong Relationships with Healthcare Providers: Penumbra has developed strong partnerships with hospitals, clinicians, and health care systems. This network facilitates the adoption of its products and creates a loyal customer base.
-
Focus on Education and Training: The company invests in educating healthcare providers about its products and the procedures they support. This not only promotes the effective use of its devices but also establishes Penumbra as a thought leader in the field.
-
Agility and Adaptability: As a midsize company, Penumbra is often more agile and able to adapt quickly to changes in the market compared to larger, more bureaucratic competitors. This flexibility can lead to rapid innovation and responsiveness to customer needs.
-
Commitment to Quality and Safety: Penumbra prioritizes high standards in product quality and patient safety. Its commitment to these principles builds trust with healthcare professionals and improves the company's reputation in the market.
-
Diversified Product Portfolio: Penumbra's investment in a broad range of products allows it to serve various segments within the vascular market, hedging against risks associated with market fluctuations in any one area.
These competitive advantages contribute to Penumbra’s strong position within the market, helping to differentiate it from its rivals and potentially leading to sustained growth and profitability.
Penumbra Inc, a medical device company focused on innovative solutions for neurovascular and peripheral vascular diseases, faces several risks and challenges in the near future:
-
Regulatory Risks: As a medical device manufacturer, Penumbra is subject to strict regulatory oversight from agencies like the FDA. Changes in regulations or increased scrutiny could delay product approvals and affect market entry.
-
Market Competition: The medical device industry is highly competitive, with established firms and new entrants continuously evolving. Penumbra must innovate while also defending its market share against competitors offering similar products.
-
Technological Advancements: Keeping pace with rapid technological advancements in medical devices is crucial. Failing to innovate or improve product offerings could lead to obsolescence.
-
Reimbursement Challenges: Securing reimbursement from insurers for new devices can be challenging. If insurers do not cover Penumbra’s products, this could limit market acceptance and sales potential.
-
Supply Chain Disruptions: Global supply chain challenges, including shortages of critical components or raw materials, can impact production schedules and costs.
-
Litigation Risks: As with many medical device companies, Penumbra could face lawsuits related to product liability, which can lead to significant financial and reputational damage.
-
Intellectual Property Issues: Protecting intellectual property is vital. Penumbra could encounter challenges related to patent infringement, or they may face difficulty in securing and maintaining patents for their innovations.
-
Economic Factors: Economic downturns can lead to decreased healthcare spending, which may impact sales. Additionally, changes in healthcare policy can affect the entire industry.
-
Talent Acquisition and Retention: Attracting and retaining skilled employees, especially in engineering and regulatory affairs, can be a challenge in a competitive industry.
-
Product Mix and Development Failure: Relying heavily on a specific product line may pose risks if market demand shifts. Additionally, failures in product development could lead to wasted resources and lost opportunities.
These factors will require careful strategic planning and mitigation efforts to ensure Penumbra Inc. continues to thrive in the evolving healthcare landscape.
Revenue & Expenses Breakdown
Penumbra Inc
Balance Sheet Decomposition
Penumbra Inc
Current Assets | 891.8m |
Cash & Short-Term Investments | 291m |
Receivables | 176.1m |
Other Current Assets | 424.7m |
Non-Current Assets | 587.4m |
PP&E | 269.7m |
Intangibles | 173.3m |
Other Non-Current Assets | 144.4m |
Current Liabilities | 153.2m |
Accounts Payable | 33.2m |
Accrued Liabilities | 116.4m |
Other Current Liabilities | 3.6m |
Non-Current Liabilities | 221.7m |
Long-Term Debt | 22.2m |
Other Non-Current Liabilities | 199.4m |
Earnings Waterfall
Penumbra Inc
Revenue
|
1.2B
USD
|
Cost of Revenue
|
-399.2m
USD
|
Gross Profit
|
764.6m
USD
|
Operating Expenses
|
-652.8m
USD
|
Operating Income
|
111.8m
USD
|
Other Expenses
|
-77.3m
USD
|
Net Income
|
34.5m
USD
|
Free Cash Flow Analysis
Penumbra Inc
USD | |
Free Cash Flow | USD |
In Q3 2024, Penumbra reported $301 million in revenue, an 11.1% increase year-over-year, led by a 21.2% growth in its U.S. thrombectomy business. The launch of new products such as Lightning Flash 2.0 is driving this uptick. Gross margins improved to 66.5%, with expectations to exceed 70% within 18 to 24 months. Non-GAAP operating income rose to $40.3 million, reflecting efficient operations. Importantly, total revenue guidance for 2024 remains between $1.18 billion and $1.2 billion, while U.S. thrombectomy growth guidance is adjusted upwards to 24-25%. The company anticipates continued positive cash flow trends moving forward.
What is Earnings Call?
PEN Profitability Score
Profitability Due Diligence
Penumbra Inc's profitability score is 52/100. The higher the profitability score, the more profitable the company is.
Score
Penumbra Inc's profitability score is 52/100. The higher the profitability score, the more profitable the company is.
PEN Solvency Score
Solvency Due Diligence
Penumbra Inc's solvency score is 87/100. The higher the solvency score, the more solvent the company is.
Score
Penumbra Inc's solvency score is 87/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
PEN Price Targets Summary
Penumbra Inc
According to Wall Street analysts, the average 1-year price target for PEN is 238.8 USD with a low forecast of 191.9 USD and a high forecast of 273 USD.
Dividends
Current shareholder yield for PEN is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Ownership
PEN Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Penumbra, Inc. engages in the design, development, manufacture, and marketing of innovative medical devices. The company is headquartered in Alameda, California and currently employs 3,800 full-time employees. The company went IPO on 2015-09-18. The firm designs, develops, manufactures, and markets products and has a portfolio that focuses on medical conditions in markets with unmet need. The company is focused on developing, manufacturing, and marketing products for use by specialist physicians and healthcare providers. The company is focused on developing and building its portfolio of products, including its thrombectomy, embolization, access, and immersive healthcare technologies. The company has developed a product portfolio that includes seven product families within its major markets, in which its neuro products include Thrombectomy, Embolization, Access, and Neurosurgical Tools. Its vascular products include Thrombectomy and Embolization. The firm's immersive healthcare product is Immersive 3D Computer-based Technology Platform. The firm sells its products to healthcare providers primarily through its direct sales organization in the United States, Europe, Canada, and Australia.
Contact
IPO
Employees
Officers
The intrinsic value of one PEN stock under the Base Case scenario is 106.95 USD.
Compared to the current market price of 244.84 USD, Penumbra Inc is Overvalued by 56%.